A multiple ascending dose study to determine ART26.12 in healthy volunteers
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs ART 2612 (Primary)
- Indications Chemotherapy-induced damage; Peripheral neuropathies
- Focus Adverse reactions
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to Artelo Biosciences media release, company shows intention to begin a multiple ascending dose study evaluating ART26.12 in healthy volunteers planned for the second half of 2025.